Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data

被引：9

作者：

Dao, Kim ^{[1
,2
]}

Vedy, Dana

Lopez, Jose ^{[3
]}

Staneczek, Olivier ^{[3
]}

Buclin, Thierry ^{[1
,2
]}

Livio, Francoise ^{[1
]}

机构：

[1] CHU Vaudois, Div Clin Pharmacol, Dept Labs, CH-1011 Lausanne, Switzerland

[2] Univ Lausanne, Lausanne, Switzerland

[3] Clin La Prairie, Clarens, Switzerland

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2013年 / 97卷 / 02期

关键词：

CHRONIC MYELOID-LEUKEMIA; DASATINIB; MESYLATE;

D O I：

10.1007/s12185-012-1250-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：299 / 300

页数：2

共 10 条

[1] Joining the DoTS: new approach to classifying adverse drug reactions [J].

Aronson, JK ;

Ferner, RE .

BRITISH MEDICAL JOURNAL, 2003, 327 (7425) :1222-1225

[2] Hypersensitivity pneumonitis related to imatinib mesylate [J].

Bergeron, A ;

Bergot, E ;

Vilela, G ;

Ades, L ;

Devergie, A ;

Espérou, H ;

Socié, G ;

Calvo, F ;

Gluckman, E ;

Ribaud, P ;

Rousselot, P ;

Tazi, A .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4271-4272

[3] Lung abnormalities after dasatinib treatment for chronic myeloid leukemia -: A case series [J].

Bergeron, Anne ;

Rea, Delphine ;

Levy, Vincent ;

Picard, Clement ;

Meignin, Veronique ;

Tamburini, Jerome ;

Bruzzoni-Giovanelli, Heriberto ;

Calvo, Fabien ;

Tazi, Abdellatif ;

Rousselot, Philippe .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (08) :814-818

[4] Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib [J].

Day, Elizabeth ;

Waters, Beatrice ;

Spiegel, Katrin ;

Alnadaf, Tanja ;

Manley, Paul W. ;

Buchdunger, Elisabeth ;

Walker, Christoph ;

Jarai, Gabor .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 599 (1-3) :44-53

[5] Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib [J].

Delomas, Thomas ;

Darne, Christian ;

Besson, Caroline .

LEUKEMIA & LYMPHOMA, 2012, 53 (02) :332-333

[6] Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms [J].

Grimison, P ;

Goldstein, D ;

Schneeweiss, J ;

Murray, N .

INTERNAL MEDICINE JOURNAL, 2005, 35 (02) :136-137

[7] Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib [J].

Hantschel, Oliver ;

Rix, Uwe ;

Superti-Furga, Giulio .

LEUKEMIA & LYMPHOMA, 2008, 49 (04) :615-619

[8] Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib [J].

Manley, Paul W. ;

Stiefl, Nikolaus ;

Cowan-Jacob, Sandra W. ;

Kaufman, Susan ;

Mestan, Juergen ;

Wartmann, Markus ;

Wiesmann, Marion ;

Woodman, Richard ;

Gallagher, Neil .

BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (19) :6977-6986

[9] Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate [J].

Ohnishi, K. ;

Sakai, F. ;

Kudoh, S. ;

Ohno, R. .

LEUKEMIA, 2006, 20 (06) :1162-1164

[10] Treatment options for chronic myeloid leukemia [J].

Tanaka, Maria Florencia ;

Kantarjian, Hagop ;

Cortes, Jorge ;

Ohanian, Maro ;

Jabbour, Elias .

EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (06) :815-828

← 1 →